Co-Authors
This is a "connection" page, showing publications co-authored by JOHN FREDERICK DE GROOT and MARTA PENAS-PRADO.
Connection Strength
1.745
-
CATNON interim results: another triumph of upfront chemotherapy in glioma. Neuro Oncol. 2017 10 01; 19(10):1287-1288.
Score: 0.616
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.183
-
Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 05; 112:83-93.
Score: 0.171
-
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
Score: 0.166
-
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494.
Score: 0.141
-
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
Score: 0.125
-
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032.
Score: 0.056
-
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab141.
Score: 0.051
-
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347.
Score: 0.050
-
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073.
Score: 0.050
-
Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neurooncol Pract. 2020 Dec; 7(6):613-619.
Score: 0.046
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.046
-
Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117.
Score: 0.044